Strides Pharma rises on USFDA nod for Potassium Chloride Oral Solution

Aarti Industries

18/11/2022 07:50

** Shares of Strides Pharma Science  SRID.NS  rise as much
as 2.85% to 340 Indian rupees
    ** About 314,445 shares traded as of 0727 GMT, nearly 0.75X
the 30-day average of 4,33,128
    ** Co's subsidiary Strides Pharma Global Pte, Singapore
secures approval from U.S. drug regulator for Potassium Chloride
Oral Solution USP, 40 mEq/15ML
    ** The produce is a bioequivalent to rival Genus
Lifesciences' reference-listed drug of the same name
    ** The drug will be made at Strides' Bengaluru facility
    ** The entire Potassium Chloride range of products for
Strides Pharma has a cumulative market opportunity of $330 mln,
as per IQVIA
    ** All four analysts tracking the company maintain "buy" or
higher, median PT is 452.59 Indian rupees
 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com))